Developer Submits BLA for TLX250-CDx Kidney Cancer Imaging in ccRCC
TLX250-CDx elicited a mean sensitivity of 85.5% and a mean specificity of 87.0% in patients with indeterminate renal masses in the phase 3 ZIRCON trial.
Satri-cel Improves PFS in CLDN18.2+ Advanced Gastric/GEJ Cancers
Treatment with satricabtagene autoleucel met the primary end point of progression-free survival in the phase 2 CT041-ST-01 trial.
Psilocybin May Elicit Positive Personality Changes in Cancer Populations
A pooled analysis of 2 trials show that psilocybin-assisted psychotherapy may provide mental health benefits for patients with cancer.
Datopotamab Deruxtecan EU Application Is Voluntarily Withdrawn for NSCLC
Feedback from the European Medicines Agency following results of the phase 3 TROPION-Lung01 informed the marketing authorization application withdrawal.
FDA Receives NDA for Dordaviprone in Recurrent H3 K27M+ Glioma
Developers have requested priority review status for dordaviprone as a treatment for patients with recurrent H3 K27M-mutated glioma.
Avutometinib With Defactinib Accepted for Review by FDA in Recurrent LGSOC
Avutometinib/defactinib was granted priority review by the FDA in the treatment of patients with recurrent, KRAS-mutant low-grade serous ovarian cancer.
Pembrolizumab Added to Preoperative Radiotherapy and Surgery Enhances DFS in Sarcoma
The SU2C-SARC032 study evaluating pembrolizumab plus radiotherapy and surgery found the regimen was well tolerated with infrequent surgical complications.
FLAURA/FLAURA2 Regimens as Treatment Options for NSCLC
The discussion on NSCLC narrowed in on findings out of recent clinical trials, particularly involving a combination regimen of osimertinib and chemotherapy.
CAR T-Cell Therapy Debate in Leukemia/Lymphoma Subtypes
A Satellite Sessions event that took place at Fred Hutchinson Cancer Center and discussed treatments surrounding LCL and CLL.
Nivolumab/Ipilimumab Combo Elicits Further PFS Benefit in Frontline MSI-H/dMMR mCRC
Updated efficacy findings from the phase 3 CheckMate-8HW trial also showed fewer grade 3/4 adverse events with nivolumab/ipilimumab vs chemotherapy.
Integrating Acalabrutinib Plus Bendamustine/Rituximab in the Frontline MCL Treatment Protocol
Brad S. Kahl, MD, and Tycel Phillips, MD, discussed the use of acalabrutinib plus bendamustine and rituximab for patients with untreated MCL.
Appropriately De-Escalating Talquetamab to Monthly Dosing in Multiple Myeloma
An unusual patient case was presented during a Frontline Forum where experts worked through how to appropriately treat a patient who was having consistent fevers and pain.
Afatinib/Osimertinib Treatment Combinations in EGFR-Mutated Advanced NSCLC
As part of a Satellite Sessions program focused on the Cleveland Clinic and surrounding institutions, CancerNetwork hosted a panel discussion on treatment options for patients with EGFR-mutated NSCLC.
Bria-IMT Cancer Vaccine Shows Efficacy, Tolerability in Advanced Breast Cancer
A phase 1/2 study showed that treatment with cyclophosphamide, SV-BR-1-GM, and retifanlimab yields favorable survival data in heavily pretreated patients with breast cancer.
LumiSystem in Lumpectomy May Reduce or Omit Radiation in Breast Cancer
Broader margins used in lumpectomies can lead to a reduced radiation target area in patients with breast cancer, according to results from a study presented at the 2024 SABCS.
Data Show Enduring Efficacy with Anito-cel in R/R Multiple Myeloma
Anito-cel produced no delayed or non–immune effector cell–associated neurotoxicity syndrome among patients with multiple myeloma.
CAR T-Cell Therapy Is a Desirable Option in Second-Line Multiple Myeloma
During the 2024 IMS Annual Meeting, colleagues gathered to discuss the latest advancements in multiple myeloma.
Determining Suitable Radioligand Therapy Use in Neuroendocrine Tumors
Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.
Discussing, Managing, and Treating HER2+ Breast Cancer From the Patient’s Perspective
In a From All Angles program, a patient and her treating physician spoke about the initial diagnosis, care coordination, communication, and the adverse effects observed.
Ivonescimab/Chemo Combo Yields Positive Efficacy and Safety Results in TNBC
Zanidatamab/Evorpacept Combo Yields Promising Activity in HER2+ Breast Cancer
Phase 1b/2 data show antitumor activity with zanidatamab/evorpacept, including among heavily pretreated patients with HER2-low metastatic breast cancer.
Longer Follow-Up Data Maintain Lasting Responses With Amivantamab/ Lazertinib in EGFR-Mutant NSCLC
Joshua K. Sabari, MD, and Sandip P. Patel, MD, discussed long-term findings from the phase 3 MARIPOSA trial.
Neoadjuvant Pembrolizumab Plus RT May Enhance DFS Outcomes in Sarcomas
Identifying HER2 Mutations for T-DXd Use in NSCLC
The Oncology Brothers spoke with Benjamin P. Levy, MD, regarding treatment updates for patients with NSCLC with HER2 expression.
FDA Approves Subcutaneous Nivolumab in All Solid Tumor Indications
Data from CheckMate-67T support the approval of subcutaneous nivolumab in patients with solid tumors across all previously approved nivolumab indications.
Experts Discuss Choosing Bispecifics and Sequencing Options in Multiple Myeloma
During the 2024 IMS conference, teams from Cleveland, Ohio, and New York, New York, met to debate the latest advances in multiple myeloma.
FDA Approves Tislelizumab/Chemo in Gastric/GEJ Adenocarcinoma
Data from the RATIONALE 305 trial support the approval of tislelizumab/chemotherapy in unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma.
Arlo-cel Shows Promising Efficacy in Pretreated R/R Multiple Myeloma
Arlo-cel yields responses among patient subgroups, including those with triple class–refractory disease and extramedullary disease.
Tislelizumab Triplet Shows Meaningful Responses, PFS in Metastatic TNBC
Phase 2 data indicate that CD8 status may serve as a biomarker for predicting treatment efficacy with tislelizumab-based treatment in TNBC.
Tirzepatide May Increase AEs in HR+/HER2– Breast Cancer Treatment
The FITWISE clinical trial assessed the safety and tolerability of breast cancer treatments when patients use tirzepatide.
